Some SRPK/CLK inhibitors generate aberrant alternative splicing that protects against Duchenne muscular dystrophy by promoting a splice event that skips an inherited deleterious mutation (96), whereas other CLK inhibitors may protect against exon-skipping mutations in Alzheimer’s disease (97). Here, CLK1 is linked to Duchenne muscular dystrophy.